<DOC>
	<DOC>NCT00064701</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of tacrolimus/mycophenolate mofetil (MMF), cyclosporine/MMF and tacrolimus modified release/MMF in de novo kidney transplant recipients.</brief_summary>
	<brief_title>Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description>This was a 3 arm randomized, open-label, comparative, multi-center study in de novo kidney transplant recipients at 60 centers in the U.S., Canada and Brazil. The study consisted of a 1-year post-transplant efficacy and safety study with a clinical continuation phase of a minimum of 2 years or until commercial availability of tacrolimus modified release, unless the Data Safety Monitoring Board or sponsor specified otherwise.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Recipient of a primary or retransplanted nonhuman leukocyte antigen (HLA)identical living or nonHLAidentical cadaveric kidney transplant Age greater or equal to 12 years Recipient or donor is known seropositive for human immunodeficiency virus (HIV) Has current malignancy or history of malignancy Has significant liver disease Has uncontrolled concomitant infection or any other unstable medical condition Is receiving everolimus or enteric coated mycophenolic acid at any time during the study Received kidney with a cold ischemia time of equal or more than 36 hours Received kidney transplant from a cadaveric donor equal or more than 60 years of age Received intravenous immunoglobulin (IVIG) therapy prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>De Novo Kidney Transplant</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>PrografÂ®</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>tacrolimus</keyword>
</DOC>